IDEXX Laboratories, Inc. (IDXX) VP Brian P. Mckeon Sells 6,602 Shares

IDEXX Laboratories, Inc. (NASDAQ:IDXX) VP Brian P. Mckeon sold 6,602 shares of the stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $181.36, for a total value of $1,197,338.72. Following the completion of the sale, the vice president now owns 47,040 shares of the company’s stock, valued at $8,531,174.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of IDEXX Laboratories, Inc. (IDXX) traded up $2.87 on Wednesday, reaching $178.26. The company’s stock had a trading volume of 1,000,269 shares, compared to its average volume of 620,773. The company has a debt-to-equity ratio of -11.26, a quick ratio of 0.80 and a current ratio of 0.97. The firm has a market capitalization of $15,550.00, a price-to-earnings ratio of 60.63, a P/E/G ratio of 2.15 and a beta of 0.58. IDEXX Laboratories, Inc. has a one year low of $140.63 and a one year high of $198.73.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Thursday, February 1st. The company reported $0.77 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.04. The company had revenue of $506.00 million for the quarter, compared to analyst estimates of $490.51 million. IDEXX Laboratories had a negative return on equity of 432.19% and a net margin of 13.36%. The firm’s revenue for the quarter was up 14.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.58 earnings per share. analysts anticipate that IDEXX Laboratories, Inc. will post 4.09 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. D.A. Davidson & CO. raised its position in IDEXX Laboratories by 160.4% in the second quarter. D.A. Davidson & CO. now owns 625 shares of the company’s stock valued at $100,000 after purchasing an additional 385 shares during the period. BB&T Investment Services Inc. purchased a new stake in IDEXX Laboratories in the second quarter valued at $104,000. Zions Bancorporation purchased a new stake in IDEXX Laboratories in the third quarter valued at $162,000. Benjamin F. Edwards & Company Inc. raised its position in IDEXX Laboratories by 1,000.0% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 1,100 shares of the company’s stock valued at $172,000 after purchasing an additional 1,000 shares during the period. Finally, SignalPoint Asset Management LLC purchased a new stake in IDEXX Laboratories in the fourth quarter valued at $200,000. 86.50% of the stock is currently owned by institutional investors.

Several research analysts have recently issued reports on the company. Piper Jaffray Companies lifted their price target on IDEXX Laboratories to $211.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. Bank of America lifted their price target on IDEXX Laboratories from $200.00 to $220.00 and gave the company a “buy” rating in a research report on Friday, February 2nd. BidaskClub upgraded IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, January 31st. Zacks Investment Research cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Finally, Canaccord Genuity reiterated a “buy” rating and set a $210.00 price target on shares of IDEXX Laboratories in a research report on Monday, January 29th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $194.00.

ILLEGAL ACTIVITY NOTICE: “IDEXX Laboratories, Inc. (IDXX) VP Brian P. Mckeon Sells 6,602 Shares” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/15/idexx-laboratories-inc-idxx-vp-brian-p-mckeon-sells-6602-shares.html.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Insider Buying and Selling by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply